Pharmacotherapy for nontuberculous mycobacterial pulmonary disease

3Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

Purpose: To provide an updated review of the diagnosis and pharmacotherapy of nontuberculous mycobacteria pulmonary disease (NTM-PD) and summarize guideline recommendations for an interdisciplinary treatment approach. Summary: A systemic approach was taken in which all articles in English in MEDLINE and PubMed were reviewed. The US National Library of Medicine's DailyMed database was used to assess drug package inserts. Analysis of NTM treatment guidelines is summarized in the article with a focus on medications, dosing, interactions, and medication monitoring. Conclusion: It is critical to manage patients with NTM with a multidisciplinary team approach. Treatment is prolonged and expensive, and the potential for drug toxicity, adverse effects, and drug interactions requires monitoring. Clinical pharmacists play a role in the management of NTM.

Cite

CITATION STYLE

APA

Velagapudi, M., Sanley, M. J., Ased, S., Destache, C., & Malesker, M. A. (2022, March 15). Pharmacotherapy for nontuberculous mycobacterial pulmonary disease. American Journal of Health-System Pharmacy. Oxford University Press. https://doi.org/10.1093/ajhp/zxab422

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free